Published 3 months ago

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen has announced that it will discontinue the sale and development of the Alzheimer's drug Aduhelm, refocusing efforts on their newly approved drug Leqembi.
The decision to drop Aduhelm is not due to safety or efficacy concerns, and the Swiss company Neurimmune will regain full rights to the medicine.
Biogen will redistribute resources from Aduhelm to other Alzheimer's treatments in their portfolio, such as BIIB080.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

Associated Press News

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago. The drugmaker also

3 months ago·United States

Read Full Article

USA Today

Biogen ditches Aduhelm, an Alzheimer's drug that was approved amid controversy

Biogen will give up ownership and halt sales of Aduhuelm, an Alzheimer's disease drug that met skepticism and scrutiny following its 2021 approval.

3 months ago·United States

Read Full Article

abc News

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm

3 months ago·United States

Read Full Article

KRDO

Biogen discontinues Alzheimer’s medication Aduhelm

By Carma Hassan and Jen Christensen, CNN (CNN) — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company said in a statement Wednesday. “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs. We pla…

3 months ago·Colorado Springs, United States

Read Full Article

KIFI

Biogen discontinues Alzheimer’s medication Aduhelm

By Carma Hassan, CNN (CNN) — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company said in a statement on Wednesday. “As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient needs. We plan to further adva…

3 months ago·Idaho Falls, United States

Read Full Article